Does wearing a noseclip during inhalation improve lung deposition?

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 17, Issue 2, 2004, Pages 116-122

  Köhler, Elke ^a   Sollich, Veronika ^a   Schuster Wonka, Renate ^a   Hühnerbein, Jürgen ^a   Jorch, Gerhard ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Cystic fibrosis; Inhalation; Lung deposition; Noseclip; Sodium cromoglycate; Urinary excretion

Indexed keywords

CROMOGLYCATE DISODIUM;

ADOLESCENT; ADULT; AIRWAY DYNAMICS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG HALF LIFE; FEMALE; HUMAN; INHALATION; LUNG FUNCTION; MALE; NEBULIZATION; NOSE OBSTRUCTION; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RESIDUE ANALYSIS; SCHOOL CHILD; STATISTICAL ANALYSIS; URINARY EXCRETION;

ADMINISTRATION, INHALATION; ADOLESCENT; BIOLOGICAL AVAILABILITY; CHILD; CROMOLYN SODIUM; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; NOSE; RESPIRATORY FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; SURGICAL INSTRUMENTS; TREATMENT OUTCOME;

EID: 3242677732     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/0894268041457192     Document Type: Article

References (23)

1. Geller, D.E., W.H. Pitlick, P.A. Nardella, et al. 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219-226.
2. Coates, A.L., L. Dinh, C.F. MacNeish, et al. 2000. Accounting for radioactivity before and after nebulization of tobramycin to ensure accuracy of quantification of lung deposition. J. Aerosol Med. 13:169-178.
3. Heinzl, B., E. Eber, B. Oberwaldner, et al. 2002. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: A pilot study. Pediatr. Pulmonol. 33:32-37.
4. Dequin, P.F., F. Faurisson, E. Lemarie, et al. 2001. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur. Respir. J. 18:316-322.
5. Kano, S., T. Hirose, and S. Nishima. 1996. Change in osmolarity of disodium cromoglycate solution and protection against exercise-induced bronchospasm in children with asthma. Eur. Respir. J. 9:1891-1895.
6. Eisenberg, J., M. Pepe, J. Williams-Warren, et al. 1997. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic systems. Chest 111:955-962.
7. Meier, R., G.L. Hall, F.H. Sennhauser, et al. 2001. Wearing a noseclip improves nebulised aerosol delivery. Swiss Med. Wkly. 131:495-497.
8. Aswania, O.A, S.A Corlett, and H. Chrystyn. 1999. Relative bioavailability of sodium cromoglycate to lung following inhalation, using urinary excretion. Br. J. Pharmacol. 47:613-618.
9. Aswania, O., and H. Chrystyn. 2002. Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation. Biopharm. Drug Dispos. 23:159-163.
10. Aswania, O., and H. Chrystyn. 2001. Relative lung bioavailability of generic sodium cromoglycate inhalers used with and without a spacer device. Pulm. Pharmacol. Ther. 14:129-133.
11. Köhler, E., V. Sollich, R. Schuster-Wonka, et al. 2003. Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. J. Aerosol Med. 16:37-46.
12. Walker, S.R., M.E. Evans, A.J. Richards, et al. 1972. The fate of [14C] disodium cromoglycate in man. J. Pharm. Pharmacol. 24:525-531.
13. Neale, M.G., K. Brown, R.W. Hodder, et al. 1986. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br. J. Pharmacol. 22:373-382.
14. Benson, M.K., S.H. Curry, G.G. Mills, et al. 1973. Uptake of disodium cromoglycate in obstructive airways disease. Clin. Allergy 3:389-394.
15. Wagner, J.G. 1963. Some possible errors in the plotting and interpretation of semilogarithmic plots of blood level and urine excretion data. J. Pharm. Sci. 52:1097-1101.
16. Richards, R., C.R. Dickson, R.A. Rennwick, et al. 1987. Absorption and disposition kinetics of cromolyn sodium and influence of inhalation technique. J. Pharmacol. Exp. Ther. 241:1028-1032.
17. Moss, G.F., K.M. Jones, J.T. Ritchie, et al. 1971. Plasma levels and urinary excretion of sodium cromoglycate after inhalation by human volunteers. Toxicol. Appl. Pharmacol. 20:147-156.
18. Ilowite, J.S., J.D. Gorvoy, and G.C. Smaldone. 1987. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Dis. 136:1445-1449.
19. Vikre-Jorgensen, J., L. Agertoft, and S. Pedersen. 1997. Dose titration of nebulized budesonide in young children. Pediatr. Pulmonol. 23:270-277.
20. Agertoft, L., A. Andersen, E. Weibull, et al. 1999. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch. Dis. Child 80:241-247.
21. Bennett W.D., K.L. Zeman, and C. Kim. 1996. Variability of fine particle deposition in healthy adults: Effect of age and gender. Am. J. Resp. Crit. Care Med. 153:1641-1647.
22. Nikander, K., and H. Bisgaard. 1999. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr. Pulmonol. 28:187-193.
23. Laube, B.L., R. Jashnani, R.N. Dalby, et al. 2000. Targeting aerosol deposition in patients with cystic fibrosis-Effect of alteration in particle size and inspiratory flow rate. Chest 118:1069-1076.